The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy
about
Molecular prognostic factors in cytogenetically normal acute myeloid leukemiaStructural Basis for WDR5 Interaction (Win) Motif Recognition in Human SET1 Family Histone MethyltransferasesFLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications.Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B studyClinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise reviewMll partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemiasDisordered epigenetic regulation in MLL-related leukemia.Genetic tests to evaluate prognosis and predict therapeutic response in acute myeloid leukemia.MLL-AF9-induced leukemogenesis requires coexpression of the wild-type Mll allele.Mobile elements and viral integrations prompt considerations for bacterial DNA integration as a novel carcinogenA mobile threat to genome stability: The impact of non-LTR retrotransposons upon the human genome.High-resolution melting curve analysis, a rapid and affordable method for mutation analysis in childhood acute myeloid leukemiaPrognostically important molecular markers in cytogenetically normal acute myeloid leukemia.Mll partial tandem duplication induces aberrant Hox expression in vivo via specific epigenetic alterations.The role of therapeutic leukapheresis in hyperleukocytotic AML.Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia.Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study.Stress hematopoiesis reveals abnormal control of self-renewal, lineage bias, and myeloid differentiation in Mll partial tandem duplication (Mll-PTD) hematopoietic stem/progenitor cellsCurrent therapeutic strategies for acute myeloid leukaemia.Higher expression levels of the HOXA9 gene, closely associated with MLL-PTD and EZH2 mutations, predict inferior outcome in acute myeloid leukemia.The MLL partial tandem duplication in acute myeloid leukaemia.High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALDNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication.The Mll partial tandem duplication: differential, tissue-specific activity in the presence or absence of the wild-type alleleIs it important to decipher the heterogeneity of "normal karyotype AML"?Amplification of c-MYC and MLL Genes as a Marker of Clonal Cell Progression in Patients with Myeloid Malignancy and Trisomy of Chromosomes 8 or 11.Agglomerative epigenetic aberrations are a common event in human breast cancer.Therapeutic targeting of MLL.Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics.Epigenetics in acute myeloid leukemia.Epigenetics of hematopoiesis and hematological malignancies.Novel targeted drug therapies for the treatment of childhood acute leukemiaAdult acute myeloid leukemia with trisomy 11 as the sole abnormality is characterized by the presence of five distinct gene mutations: MLL-PTD, DNMT3A, U2AF1, FLT3-ITD and IDH2.MLL-Rearranged Leukemias-An Update on Science and Clinical Approaches.Whole-exome sequencing identified a homozygous BRDT mutation in a patient with acephalic spermatozoaAcute myeloid leukemia with normal cytogenetics.Mixed lineage leukemia protein in normal and leukemic stem cells.A systematic review and meta-analysis of the impact of WT1 polymorphism rs16754 in the effectiveness of standard chemotherapy in patients with acute myeloid leukemia.Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility.
P2860
Q26998811-8F73AB51-B7FF-405E-A312-4343B0164562Q27679498-434B574D-CB60-4B83-A75B-EBEA3A62F3FCQ27851415-5171CECB-3DCE-40F3-B6CA-E0556A2B0AB8Q27851436-A9908126-322D-4FA0-9A8D-EA370A5C952BQ28301344-9F82A3EE-0FEA-44C2-A04F-B33CDEBD16C1Q28594733-CA4E911E-4E4F-4D1C-A125-F65F4A63782BQ30422159-9A13FB53-6DE4-4600-A6D7-90AE4A73CE43Q33555627-A9088B7B-9F97-4158-B7C3-9D4500B3CD59Q33694927-C110C2B3-99A3-4C47-AFBC-B9584F550504Q34053726-2D2A5297-6254-40F2-A772-46F170849CC2Q34077410-9A2F4D17-C9A2-4EA4-8F32-BFD64A9398BDQ34154213-86EF0112-67A7-4CB6-AABB-159FEAD37EBEQ34522735-FF203172-B7E9-4E35-BF7E-9B78B5DA29D5Q35025549-AEB51A07-CB38-4986-8356-A173DB8031E4Q35148107-AB302AE1-FA25-4B2B-ADC4-EFD1FD16C57DQ35615901-539DA072-0695-417A-A84C-892F198756DEQ35724527-205DB837-417D-42E7-A87E-BF8E23BC6FE4Q35839909-02B68E30-B4D4-4933-93E0-738CAF017BC3Q36141856-A9183D87-646B-443B-957F-717287EFF49AQ36539598-C686E02C-4717-4E78-9C6B-0AE5CCACC07DQ36585150-2DC593B7-17B0-4FEA-B6EF-71FAFD48BE23Q36590734-140AD616-C89A-470A-9328-48B600F84327Q36677320-4ADE3CE0-CE24-452B-8ECB-68BD05FC065FQ36843784-F63CD0A7-419B-418F-974A-1318D532018FQ36868776-3B9FE802-C1E7-4B8E-8008-98D4D6CDAC12Q37110802-949D2BD1-D942-4D27-8978-5D5FBC12B1B7Q37181624-701A0920-BCC5-4E38-8C40-66841FAFE648Q37187180-957409CD-D43C-44D4-A5F8-0FF16AB5EE82Q37234595-FD274FAB-1B52-48B2-915C-EE8EFA9C653DQ37236994-1AD30322-2360-4933-A7F3-B9E5BEEDF22DQ37240566-ABD2EBA9-4434-4247-9B33-B339F1138029Q37343797-8887E8B2-7D14-4F43-8FDD-C552E8514BF0Q37477482-713DCC24-8125-4CC2-9D52-DB118AD2ABDCQ37593486-C393C678-3BFC-4B59-BC21-A94F209A16D3Q37633585-FC6AE1A4-00A3-4780-9BBF-6C5EA18E01F0Q37746193-D5BFF410-8A12-45E9-B39C-BE371DD60031Q38027047-580B3FF2-CA86-43D4-BB70-FA2E6FC138F6Q38100107-7F082C4E-218B-4E84-8C84-66E5CEF8D825Q38661750-DF17BFD9-60B7-4905-B0F7-E40B857C3010Q38703904-F5D90859-1478-4D95-A534-FEE7938D565A
P2860
The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
The MLL partial tandem duplica ...... for molecular-targeted therapy
@ast
The MLL partial tandem duplica ...... for molecular-targeted therapy
@en
type
label
The MLL partial tandem duplica ...... for molecular-targeted therapy
@ast
The MLL partial tandem duplica ...... for molecular-targeted therapy
@en
prefLabel
The MLL partial tandem duplica ...... for molecular-targeted therapy
@ast
The MLL partial tandem duplica ...... for molecular-targeted therapy
@en
P2093
P2860
P50
P1433
P1476
The MLL partial tandem duplica ...... for molecular-targeted therapy
@en
P2093
Adrienne Dorrance
Brian Becknell
Christoph Plass
Chunhui Liu
Laura J Rush
Marko I Klisovic
Martin Guimond
Matthew P Strout
Michael A Caligiuri
P2860
P304
P356
10.1182/BLOOD-2005-01-0204
P407
P577
2005-03-17T00:00:00Z